Diagnostic Tools for Eosinophilic Esophagitis
Diagnose EoE with upper endoscopy and esophageal biopsies showing ≥15 eosinophils per high-power field (or ≥60 eosinophils per mm²) in patients with symptoms of esophageal dysfunction, after excluding other causes of esophageal eosinophilia 1, 2.
Gold Standard: Endoscopy with Biopsy
The definitive diagnostic approach requires:
- Upper endoscopy (esophagogastroduodenoscopy) with systematic biopsy sampling
- Minimum of 6 biopsies from at least 2 esophageal levels (proximal and distal esophagus) 2
- Endoscopic appearance alone is insufficient—normal-appearing mucosa can still harbor eosinophilia 2
- Gastric or duodenal biopsies are no longer routinely required unless specific symptoms or endoscopic abnormalities suggest involvement 2
Important Diagnostic Update
PPIs are now classified as a treatment for EoE, not a diagnostic exclusion criterion 1. The outdated concept of "PPI-responsive esophageal eosinophilia" as a separate entity has been abandoned. You no longer need to perform a PPI trial before diagnosing EoE—if a patient has symptoms and ≥15 eos/hpf after comprehensive evaluation excluding other disorders, they have EoE regardless of PPI response 1.
Emerging Minimally Invasive Alternatives
For disease monitoring (not initial diagnosis) in established EoE patients:
Clinically Available Options
- Unsedated transnasal endoscopy (TNE): >95% completion rate, well-tolerated, reduces visit time and cost 3
- Esophageal string test (EST): >86% completion rate, correlates well with histologic eosinophil counts 3, 4
- Cytosponge/sponge-based devices: Strong correlation with disease activity through eosinophil-derived protein measurement 4
These tools are best suited for adolescents and adults after EoE diagnosis is established, not for initial diagnosis 3.
Biomarkers Under Investigation
Current research shows promise but lacks sufficient validation for routine clinical use:
Blood/Urine Biomarkers
- Peripheral eosinophil count (PEC): Most studied but demonstrates limited reliability 4
- Eosinophil-derived proteins (EDN, ECP, MBP-1): More promising but inconsistent between studies 4, 5
- Cytokines (eotaxin-3): Shows potential but requires further validation 4
Critical limitation: Most biomarker studies lack allergic controls, limiting their diagnostic specificity 3.
Complementary Diagnostic Tools
- Impedance planimetry (EndoFLIP): Assesses esophageal distensibility and stricture severity 6
- EoE Endoscopic Reference Score (EREFS): Standardizes endoscopic findings 7
- Eosinophilic Esophagitis Histologic Scoring System: Improves disease characterization 7
Clinical Assessment Tools
- Pediatric patients: PEESS v2.0 (Pediatric Eosinophilic Esophagitis Symptom Score) and PedsQL for symptom severity and quality of life 8
Common Pitfalls to Avoid
- Insufficient biopsy sampling: Taking fewer than 6 biopsies or sampling only one esophageal level reduces diagnostic sensitivity 2
- Relying on endoscopic appearance: Normal-looking mucosa does not exclude EoE 2
- Requiring PPI trial before diagnosis: This outdated approach delays diagnosis unnecessarily 1
- Using peripheral eosinophil count alone: PEC is unreliable for EoE diagnosis 4
- Implementing novel biomarkers prematurely: These require additional validation before routine clinical use 3, 4
Practical Algorithm
- Patient presents with esophageal dysfunction symptoms (dysphagia, food impaction, reflux-like symptoms in children)
- Perform upper endoscopy with ≥6 biopsies from ≥2 esophageal levels
- If ≥15 eos/hpf present: Exclude other causes of esophageal eosinophilia through comprehensive assessment
- Diagnosis confirmed: Proceed to treatment (PPIs, topical steroids, or dietary elimination)
- For monitoring: Consider minimally invasive alternatives (TNE, EST) in adolescents/adults to reduce endoscopy burden 3
The burden of repeated endoscopies for monitoring is significant 6, making the development of validated non-invasive tools a priority research area 9.